Insmed (MIL:1INSM) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1INSM Insmed Inc MIL:1INSM
50 GF Score
Price €110.38
GF Value €183.27
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Insmed Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

MIL:1INSM
50GF Score
Insmed Inc MIL:1INSM
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Insmed (MIL:1INSM) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of €110.38 is trading 39.8% below its estimated GF Value™ of €183.27. GuruFocus considers Insmed to be Possible Value Trap.

Key valuation signals for MIL:1INSM:

  • Total Noninterest Expense:
  • GF Value™: €183.27 vs. price of €110.38 (39.8% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the MIL:1INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insmed Business Description

Other Exchanges INSM:USA0JAV:UKIM8N:Germany
Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
50GF Score

Get the complete analysis for MIL:1INSM

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€110.38
Price
€183.27
GF Value